Cargando…
A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours
BACKGROUND: We completed a phase I clinical trial to test the safety and toxicity of combined treatment with cixutumumab (anti-IGF-1R antibody) and selumetinib (MEK 1/2 inhibitor). METHODS: Patients with advanced solid tumours, refractory to standard therapy received selumetinib hydrogen sulphate ca...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453594/ https://www.ncbi.nlm.nih.gov/pubmed/25268371 http://dx.doi.org/10.1038/bjc.2014.515 |
_version_ | 1782374480789635072 |
---|---|
author | Wilky, B A Rudek, M A Ahmed, S Laheru, D A Cosgrove, D Donehower, R C Nelkin, B Ball, D Doyle, L A Chen, H Ye, X Bigley, G Womack, C Azad, N S |
author_facet | Wilky, B A Rudek, M A Ahmed, S Laheru, D A Cosgrove, D Donehower, R C Nelkin, B Ball, D Doyle, L A Chen, H Ye, X Bigley, G Womack, C Azad, N S |
author_sort | Wilky, B A |
collection | PubMed |
description | BACKGROUND: We completed a phase I clinical trial to test the safety and toxicity of combined treatment with cixutumumab (anti-IGF-1R antibody) and selumetinib (MEK 1/2 inhibitor). METHODS: Patients with advanced solid tumours, refractory to standard therapy received selumetinib hydrogen sulphate capsules orally twice daily, and cixutumumab intravenously on days 1 and 15 of each 28-day cycle. The study used a 3+3 design, with a dose-finding cohort followed by an expansion cohort at the maximally tolerated dose that included pharmacokinetic and pharmacodynamic correlative studies. RESULTS: Thirty patients were enrolled, with 16 in the dose-finding cohort and 14 in the expansion cohort. Grade 3 or greater toxicities included nausea and vomiting, anaemia, CVA, hypertension, hyperglycaemia, and ophthalmic symptoms. The maximally tolerated combination dose was 50 mg twice daily of selumetinib and 12 mg kg(−1) every 2 weeks of cixutumumab. Two patients achieved a partial response (one unconfirmed), including a patient with BRAF wild-type thyroid carcinoma, and a patient with squamous cell carcinoma of the tongue, and six patients achieved time to progression of >6 months, including patients with thyroid carcinoma, colorectal carcinoma, and basal cell carcinoma. Comparison of pre- and on-treatment biopsies showed significant suppression of pERK and pS6 activity with treatment. CONCLUSIONS: Our study of anti-IGF-1R antibody cixutumumab and MEK 1/2 inhibitor selumetinib showed that the combination is safe and well-tolerated at these doses, with preliminary evidence of clinical benefit and pharmacodynamic evidence of target inhibition. |
format | Online Article Text |
id | pubmed-4453594 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-44535942016-01-06 A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours Wilky, B A Rudek, M A Ahmed, S Laheru, D A Cosgrove, D Donehower, R C Nelkin, B Ball, D Doyle, L A Chen, H Ye, X Bigley, G Womack, C Azad, N S Br J Cancer Clinical Study BACKGROUND: We completed a phase I clinical trial to test the safety and toxicity of combined treatment with cixutumumab (anti-IGF-1R antibody) and selumetinib (MEK 1/2 inhibitor). METHODS: Patients with advanced solid tumours, refractory to standard therapy received selumetinib hydrogen sulphate capsules orally twice daily, and cixutumumab intravenously on days 1 and 15 of each 28-day cycle. The study used a 3+3 design, with a dose-finding cohort followed by an expansion cohort at the maximally tolerated dose that included pharmacokinetic and pharmacodynamic correlative studies. RESULTS: Thirty patients were enrolled, with 16 in the dose-finding cohort and 14 in the expansion cohort. Grade 3 or greater toxicities included nausea and vomiting, anaemia, CVA, hypertension, hyperglycaemia, and ophthalmic symptoms. The maximally tolerated combination dose was 50 mg twice daily of selumetinib and 12 mg kg(−1) every 2 weeks of cixutumumab. Two patients achieved a partial response (one unconfirmed), including a patient with BRAF wild-type thyroid carcinoma, and a patient with squamous cell carcinoma of the tongue, and six patients achieved time to progression of >6 months, including patients with thyroid carcinoma, colorectal carcinoma, and basal cell carcinoma. Comparison of pre- and on-treatment biopsies showed significant suppression of pERK and pS6 activity with treatment. CONCLUSIONS: Our study of anti-IGF-1R antibody cixutumumab and MEK 1/2 inhibitor selumetinib showed that the combination is safe and well-tolerated at these doses, with preliminary evidence of clinical benefit and pharmacodynamic evidence of target inhibition. Nature Publishing Group 2015-01-06 2014-09-30 /pmc/articles/PMC4453594/ /pubmed/25268371 http://dx.doi.org/10.1038/bjc.2014.515 Text en Copyright © 2015 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Clinical Study Wilky, B A Rudek, M A Ahmed, S Laheru, D A Cosgrove, D Donehower, R C Nelkin, B Ball, D Doyle, L A Chen, H Ye, X Bigley, G Womack, C Azad, N S A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours |
title | A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours |
title_full | A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours |
title_fullStr | A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours |
title_full_unstemmed | A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours |
title_short | A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours |
title_sort | phase i trial of vertical inhibition of igf signalling using cixutumumab, an anti-igf-1r antibody, and selumetinib, an mek 1/2 inhibitor, in advanced solid tumours |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453594/ https://www.ncbi.nlm.nih.gov/pubmed/25268371 http://dx.doi.org/10.1038/bjc.2014.515 |
work_keys_str_mv | AT wilkyba aphaseitrialofverticalinhibitionofigfsignallingusingcixutumumabanantiigf1rantibodyandselumetinibanmek12inhibitorinadvancedsolidtumours AT rudekma aphaseitrialofverticalinhibitionofigfsignallingusingcixutumumabanantiigf1rantibodyandselumetinibanmek12inhibitorinadvancedsolidtumours AT ahmeds aphaseitrialofverticalinhibitionofigfsignallingusingcixutumumabanantiigf1rantibodyandselumetinibanmek12inhibitorinadvancedsolidtumours AT laheruda aphaseitrialofverticalinhibitionofigfsignallingusingcixutumumabanantiigf1rantibodyandselumetinibanmek12inhibitorinadvancedsolidtumours AT cosgroved aphaseitrialofverticalinhibitionofigfsignallingusingcixutumumabanantiigf1rantibodyandselumetinibanmek12inhibitorinadvancedsolidtumours AT donehowerrc aphaseitrialofverticalinhibitionofigfsignallingusingcixutumumabanantiigf1rantibodyandselumetinibanmek12inhibitorinadvancedsolidtumours AT nelkinb aphaseitrialofverticalinhibitionofigfsignallingusingcixutumumabanantiigf1rantibodyandselumetinibanmek12inhibitorinadvancedsolidtumours AT balld aphaseitrialofverticalinhibitionofigfsignallingusingcixutumumabanantiigf1rantibodyandselumetinibanmek12inhibitorinadvancedsolidtumours AT doylela aphaseitrialofverticalinhibitionofigfsignallingusingcixutumumabanantiigf1rantibodyandselumetinibanmek12inhibitorinadvancedsolidtumours AT chenh aphaseitrialofverticalinhibitionofigfsignallingusingcixutumumabanantiigf1rantibodyandselumetinibanmek12inhibitorinadvancedsolidtumours AT yex aphaseitrialofverticalinhibitionofigfsignallingusingcixutumumabanantiigf1rantibodyandselumetinibanmek12inhibitorinadvancedsolidtumours AT bigleyg aphaseitrialofverticalinhibitionofigfsignallingusingcixutumumabanantiigf1rantibodyandselumetinibanmek12inhibitorinadvancedsolidtumours AT womackc aphaseitrialofverticalinhibitionofigfsignallingusingcixutumumabanantiigf1rantibodyandselumetinibanmek12inhibitorinadvancedsolidtumours AT azadns aphaseitrialofverticalinhibitionofigfsignallingusingcixutumumabanantiigf1rantibodyandselumetinibanmek12inhibitorinadvancedsolidtumours AT wilkyba phaseitrialofverticalinhibitionofigfsignallingusingcixutumumabanantiigf1rantibodyandselumetinibanmek12inhibitorinadvancedsolidtumours AT rudekma phaseitrialofverticalinhibitionofigfsignallingusingcixutumumabanantiigf1rantibodyandselumetinibanmek12inhibitorinadvancedsolidtumours AT ahmeds phaseitrialofverticalinhibitionofigfsignallingusingcixutumumabanantiigf1rantibodyandselumetinibanmek12inhibitorinadvancedsolidtumours AT laheruda phaseitrialofverticalinhibitionofigfsignallingusingcixutumumabanantiigf1rantibodyandselumetinibanmek12inhibitorinadvancedsolidtumours AT cosgroved phaseitrialofverticalinhibitionofigfsignallingusingcixutumumabanantiigf1rantibodyandselumetinibanmek12inhibitorinadvancedsolidtumours AT donehowerrc phaseitrialofverticalinhibitionofigfsignallingusingcixutumumabanantiigf1rantibodyandselumetinibanmek12inhibitorinadvancedsolidtumours AT nelkinb phaseitrialofverticalinhibitionofigfsignallingusingcixutumumabanantiigf1rantibodyandselumetinibanmek12inhibitorinadvancedsolidtumours AT balld phaseitrialofverticalinhibitionofigfsignallingusingcixutumumabanantiigf1rantibodyandselumetinibanmek12inhibitorinadvancedsolidtumours AT doylela phaseitrialofverticalinhibitionofigfsignallingusingcixutumumabanantiigf1rantibodyandselumetinibanmek12inhibitorinadvancedsolidtumours AT chenh phaseitrialofverticalinhibitionofigfsignallingusingcixutumumabanantiigf1rantibodyandselumetinibanmek12inhibitorinadvancedsolidtumours AT yex phaseitrialofverticalinhibitionofigfsignallingusingcixutumumabanantiigf1rantibodyandselumetinibanmek12inhibitorinadvancedsolidtumours AT bigleyg phaseitrialofverticalinhibitionofigfsignallingusingcixutumumabanantiigf1rantibodyandselumetinibanmek12inhibitorinadvancedsolidtumours AT womackc phaseitrialofverticalinhibitionofigfsignallingusingcixutumumabanantiigf1rantibodyandselumetinibanmek12inhibitorinadvancedsolidtumours AT azadns phaseitrialofverticalinhibitionofigfsignallingusingcixutumumabanantiigf1rantibodyandselumetinibanmek12inhibitorinadvancedsolidtumours |